Cellectar Biosciences (CLRB) Other Non-Current Assets (2010 - 2026)
Cellectar Biosciences (CLRB) posted Other Non-Current Assets of $29780.0 for Q4 2025, little changed sequentially from $29780.0 in Q3 2025, and little changed YoY from $29780.0 in Q4 2024.
Cellectar Biosciences (CLRB) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Other Non-Current Assets for 16 years, with the latest figure at $29780.0 in Q4 2025.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $29780.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29780.0 (changed 0.0% YoY) and the FY2025 annual result came in at $29780.0, changed 0.0% from the prior year.
- Other Non-Current Assets was little changed at $29780.0 in Q4 2025 per CLRB's latest filing, from $29780.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $81214.0 in Q1 2022 and troughed at $6214.0 in Q1 2021.
- A 5-year average of $37336.2 and a median of $29780.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 1206.95% in 2022, then tumbled 63.33% in 2023.
- Over 5 years, Other Non-Current Assets stood at $6214.0 in 2021, then surged by 1206.95% to $81214.0 in 2022, then slumped by 63.33% to $29780.0 in 2023, then changed by 0.0% to $29780.0 in 2024, then changed by 0.0% to $29780.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $29780.0, $29780.0, and $29780.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | 23,566.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23,566.00 |
| Dec 31, 2025 | 29,780.00 |
| Sep 30, 2025 | 29,780.00 |
| Jun 30, 2025 | 29,780.00 |
| Mar 31, 2025 | 29,780.00 |
| Dec 31, 2024 | 29,780.00 |
| Sep 30, 2024 | 29,780.00 |
| Jun 30, 2024 | 29,780.00 |
| Mar 31, 2024 | 29,780.00 |
| Dec 31, 2023 | 29,780.00 |
| Sep 30, 2023 | 29,780.00 |
| Jun 30, 2023 | 29,780.00 |
| Mar 31, 2023 | 69,431.00 |
| Dec 31, 2022 | 81,214.00 |
| Sep 30, 2022 | 81,214.00 |
| Jun 30, 2022 | 81,214.00 |
| Mar 31, 2022 | 81,214.00 |
| Dec 31, 2021 | 6,214.00 |
| Sep 30, 2021 | 6,214.00 |
| Jun 30, 2021 | 6,214.00 |